Geron Corp. (GERN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1154775,
    "name": "Geron Corp.",
    "stock_name": "Geron Corp.",
    "full_name": "Geron Corp.",
    "name_url": "stocks-analysis/geron-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.27",
    "chg": 0.04,
    "chgp": "3.25%",
    "dir": 1,
    "prev_price": "1.23",
    "mcapval": "874.08",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US3741631036",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.63 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/geron-corp-1154775-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Geron Corp. Hits Day Low of $1.04 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/geron-corp-hits-day-low-of-104-amid-price-pressure-3676125",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GeronCorp_priceRelatedfactors_3676125.png",
        "date": "2025-11-06 16:11:44",
        "description": "Geron Corp. faced a notable decline in its stock today, contrasting sharply with the S&P 500's performance. The company has struggled significantly over the past year and three years, despite reporting positive net sales for the last three quarters and maintaining strong institutional investor support."
      },
      {
        "title": "Geron Corp. Stock Hits Day High with Strong 7.87% Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/geron-corp-stock-hits-day-high-with-strong-787-intraday-surge-3585855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/GeronCorp_priceRelatedfactors_3585855.png",
        "date": "2025-10-01 16:10:03",
        "description": "Geron Corp. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P 500. The company has reported positive results for the last three quarters, with net sales of USD 88.64 million and strong institutional investor confidence, despite facing long-term challenges."
      },
      {
        "title": "Is Geron Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-geron-corp-technically-bullish-or-bearish-3545707",
        "imagepath": "",
        "date": "2025-09-20 19:16:44",
        "description": "As of 1 August 2025, the technical trend for Geron Corp. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish, indicating mixed signals. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential upward momentum over a longer timeframe. However, the daily moving averages are bearish, and both the weekly Bollinger Bands and KST are mildly bearish. The Dow Theory indicates a mildly bearish stance on the weekly chart with no trend on the monthly.\n\nIn terms of performance, Geron Corp. has significantly underperformed compared to the S&P 500, with a year-to-date return of -62.71% versus the S&P's 12.22%, and a one-year return of -70.8% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bearish with some strength in the weekly MACD and monthly RSI, but overall performance remains weak...."
      },
      {
        "title": "Is Geron Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-geron-corp-overvalued-or-undervalued-3542392",
        "imagepath": "",
        "date": "2025-09-20 17:51:44",
        "description": "As of 8 August 2024, the valuation grade for Geron Corp. has moved from does not qualify to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 3.80, an EV to EBIT of -6.45, and an EV to EBITDA of -6.51, all of which suggest that the company's valuation is not supported by its financial performance.\n\nIn comparison to peers, Geron Corp. has a P/E ratio of -10.13, while Rhythm Pharmaceuticals, Inc. has a much steeper P/E of -36.41, and Aurinia Pharmaceuticals, Inc., which is rated fair, has a P/E of 20.87. The stark contrast in valuations highlights the challenges Geron Corp. faces in the market. Furthermore, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -62.71% compared to the index's 12.22%, reinforcing th..."
      }
    ],
    "total": 9,
    "sid": "1154775",
    "stock_news_url": "https://www.marketsmojo.com/news/geron-corp-1154775"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Geron Corp. Hits Day Low of $1.04 Amid Price Pressure

2025-11-06 16:11:44

Geron Corp. faced a notable decline in its stock today, contrasting sharply with the S&P 500's performance. The company has struggled significantly over the past year and three years, despite reporting positive net sales for the last three quarters and maintaining strong institutional investor support.

Geron Corp. Stock Hits Day High with Strong 7.87% Intraday Surge

2025-10-01 16:10:03

Geron Corp. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P 500. The company has reported positive results for the last three quarters, with net sales of USD 88.64 million and strong institutional investor confidence, despite facing long-term challenges.

Is Geron Corp. technically bullish or bearish?

2025-09-20 19:16:44

As of 1 August 2025, the technical trend for Geron Corp. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish, indicating mixed signals. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential upward momentum over a longer timeframe. However, the daily moving averages are bearish, and both the weekly Bollinger Bands and KST are mildly bearish. The Dow Theory indicates a mildly bearish stance on the weekly chart with no trend on the monthly. In terms of performance, Geron Corp. has significantly underperformed compared to the S&P 500, with a year-to-date return of -62.71% versus the S&P's 12.22%, and a one-year return of -70.8% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bearish with some strength in the weekly MACD and monthly RSI, but overall performance remains weak....

Is Geron Corp. overvalued or undervalued?

2025-09-20 17:51:44

As of 8 August 2024, the valuation grade for Geron Corp. has moved from does not qualify to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 3.80, an EV to EBIT of -6.45, and an EV to EBITDA of -6.51, all of which suggest that the company's valuation is not supported by its financial performance. In comparison to peers, Geron Corp. has a P/E ratio of -10.13, while Rhythm Pharmaceuticals, Inc. has a much steeper P/E of -36.41, and Aurinia Pharmaceuticals, Inc., which is rated fair, has a P/E of 20.87. The stark contrast in valuations highlights the challenges Geron Corp. faces in the market. Furthermore, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -62.71% compared to the index's 12.22%, reinforcing th...

View All News